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An improved method is presented for the detection of 
systemically administered photosensitizing drugs in hu-
mans. Test agents were injected intradermally il! physi-
ologic saline and then exposed to broad spectrum radia-
tion from a Xenon solar simulator. Several clinically 
recognized photosensitizers were identified by this tech-
nique. The activating spectrum depended on the test 
drug. Sulfonamides and vinblastin were activated by 
sunburning erythemic radiation (UV -B), while tetracy-
clines, nalidixic acid and phenothiazines by near UV 
(UV-A), and chlorothiazide by both. It is suggested that 
intradermal phototesting offers a means of verifying the 
phototoxic potential of agents suspected clinically of 
provoking a photosensitivity eruption. 
The importance of phototoxic drug reactions came to the 
fore following the widespread use of phenothiazine tranquilizers 
and demethylchlortetracycline. As the catalogue of new drugs 
has expanded, the number of agents capable of causing photo-
sensitivity reactions has grown. Generally, the phototoxic po-
tentiality of new drugs is recognized after and not before their 
introduction into commerce. This bespeaks the want of suitable 
laboratory assays for identifying photosensitizing compounds. 
Ison and Blank utilized the skin of albino hairless mice for 
screening photosensitizing drugs [1]. After intraperitoneal in-
jection of the test agents, they irradiated the animals with 
fluorescent blacklights. The emission from these lamps is pri-
marily in the long ultraviolet region (UV-A, 320-400 nm). 
Tetracyclines, phenothiazines and 8-methoxypsoralen (8-MOP) 
gave positive reactions in Ison and Blank's tests, whereas chlo-
rothiazide was negative except when the animals were exposed 
to sunlight filtered through window glass. Baer and Harber [2] 
and Sams [3], utilizing a variety of artificial UV -sources, could 
not evoke positive responses with agents which were already 
recognized as being phototoxic, for example, sulfanilamide and 
chlorothiazide. Sams and Epstein, however, succeeded in pro-
ducing phototoxic reactions to demethylchlortetracycline, 
chlorpromazine and chlorothiazide in guinea pigs with natural 
sunlight [ 4]. 
Phototoxic responses have been experimentally produced in 
humans. Schorr and Monash demonstrated phototoxicity to 
tetracyclines following intradermal injection and exposure to 
sunlight [5]. Maibach, Sams and Epstein also obtained positive 
results with Mylar filtered sunlight but not with artificial UV-
sources [6]. It became evident that a light source with high UV-
A irradiance was necessary for phototesting. Subsequently, 
Kligman and Breit, using a Xenon solar simulator, were able to 
produce phototoxic reactions with most of the clinically recog-
nized photosensitizers following intradermal injection as well as 
topical application to stripped skin [7]. They found that the 
photoactivating wavelengths for all these drugs was in the UV-
A range. 
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We have reevaluated the intradermal phototesting technique 
and have become aware of inconsistencies which have made it 
necessary to amend the procedure. We report now an improved 
method for identifying systemic photosensitizing drugs using 
intradermal injections into human skin. 
MATERIALS AND METHODS 
Subjects 
These were white, healthy adult volunteers between the ages of 21 
and 32 yr. The untanned lower back served as the test site. Informed 
consent was obtained. 
Light Source 
A 150-w Xenon solar simulator with the Schott WG-320 filter was 
used (UV-B intensity= 12.2 mw/cm2). This source simulated sunlight 
only in the sunburning portion of the spectrum [8]. The output falls 
sharply in the UV-A region between 360 nm and 400 nm because of 
filtration through a colored Corning 9863 futer, which absorbs long 
ultraviolet and also visible light. In order to intensify the UV-A and 
visible light components, the Corning filter was removed. To eliminate 
erythemic radiation, the Schott WG-345 filter was inserted, providing 
a continuous spectrum of UV -A and visible light (total flux = 130 
mw/cm2; UV-A = 30 mw/cm2; visible light= 38 mw/cm2; infra-red= 
62 mw/cm2) . Intensity measurements were made by a calibrated ther-
mopile (The Eppley Laboratories, Newport, R.I.) . 
Test Drugs 
A volume of 0.1 ml was injected intradermally through a tuberculin 
syringe with a 27-gauge needle. 
Soluble agents were dissolved in physiologic saline. These included 
sulfanilamide, colchicine, chlorpromazine hydrochloride and prochlor-
perazine sulfonate. Drugs in ampoules were diluted with saline. These 
were sodium tolbutamide (i.v., Orinase, Upjohn) , vinblastin sulfate 
(Velban, Lilly), chlorothiazide (i.v., Diuril, M.S.D.), quinidine gluconate 
(Lilly), chlordiazepoxide hydrochloride (Librium, Roche), furosemide 
(Lasix, Hoechst). 
Nalidixic acid was solubilized in 0.1 N NaOH and diluted to a 0.15% 
concentration with saline; the pH was adjusted to 7.0-7.1 with 0.1 N 
HCl and the solution sterilized by millipore futration. 
Insoluble agents were subjected to ultrasonification in physiologic 
saline (Brown sonifler) for 2 hr to provide a uniform suspension of fine 
particles. Drugs injected as suspensions included: griseofulvin, de-
methylchlortetracycline, tetracycline base and sulfapyridine. Optimal 
nonirritating concentrations, time intervals and light doses were esti-
mated from previous work and from pilot studies. Controls consisted of 
an unirradiated drug injected site and an irradiated site injected with 
saline. The sites were irradiated 10 to 15 min after injection. Responses 
were graded 24 hr later, always in relation to the control site. 
Dose-Response Studies 
Two drugs, furosemide and quinidine, were selected for investigating 
the influence of dose on the ph ototoxic response. Each subject received 
3 different concentrations of 1 drug intradermally, along with appro-
priate controls prior to irradiation as described above. The UV-A 
exposure for furosemide was 15.0 Joules/cm2 and for quinidine 8.0 
Joules/cm2. 
RESULTS 
Phototoxic reactions were obtained with all of the drugs 
except sodium tolbutamide, colchicine and chlordiazepoxide 
(Table I). Larger concentrations of these drugs were not tested 
because of irritancy. The findings permit a classification of 
phototoxic agents into 2 categories based on action spectra. 
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Reactions to sulfanilamide, sulfapyridine and vinblastin sulfate 
were provoked only by radiation containing UV-B, but not with 
UV -A and visible light. An exposure of 1 Minimal Erythema 
Dose (about 1.6 Joules/ cm2 of UV-B) produced positive re-
sponses in the majority of subjects (Table I). The remaining 
drugs gave phototoxic reactions only after exposure to UV -A 
and visible light. The dose required varied with the test agent. 
Thus with quinidine an exposure of 6 min (about 10.5 Joules of 
UV-A/ cm2) produced positive responses while the phenothia-
zines and chlorothiazide required 10 min (about 18 Joules of 
UV-A/ cm2 ). Larger doses (18 min, about 32 Joules/ cm2) were 
needed for the tetracyclines, nalidixic acid and furosemide, and 
a still larger dose (22 min, about 40 Joules of UV-A/cm2 ) was 
necessary with griseofulvin. Chlorothiazide was unusual in that 
reactions were obtained with both UV-A and with UV-B con-
taining radiation (Table I). However, much larger doses of UV-
A were required. 
The clinical reaction pattern was the same with all these 
drugs. Intense erythema and edema became apparent 4-6 hr 
after light exposure and reached maximal intensity by 24 lu:, by 
which time the sites were palpably infiltrated and raised. Grad-
ual resolution occurred over the next 3-5 days. There were no 
immediate urticarial type responses or vesicular reactions. Ir-
radiated control sites showed only pigmentation, except with 
larger exposures (22 min) where minimal erythema also devel-
oped in the majority of subjects. However, edema and infiltra-
tion were never noted. 
Dose-Response Studies 
Table II shows that for both furosemide and quinidine the 
number of subjects showing positive responses depended on the 
dose of the injected drug when the UV-exposure was held 
constant. 
DISCUSSION 
Intradermal phototesting in humans is a reliable technique 
for the identification of drugs with a photosensitizing potential. 
The method is simple and reproducible. A high intensity UV 
light source is essential. The Xenon solar simulator with the 
Corning 9863 filter removed is greatly suited for this purpose. 
A distinctive advantage is high output of long ultraviolet rays; 
most of the known phototoxic drugs are activated by this 
spectral range. We experienced many failures when we at-
tempted to reproduce our present findings with other sources, 
such as blacklight fluorescent tubes, even after prolonged ex-
posures (unpublished observations). 
It should be pointed out that test agents should only be 
assayed at nonirritating concentrations, since a strong irritant 
response may obscure a phototoxic reaction. Furthermore this 
assay serves only as a screening procedure. A positive response 
TABLE I. Phototoxicity of intradennally injected drugs 
Sulfanilamide 
Sulfapyridine 
Vinblastin 
Nalidixic acid 
Griseofulvin 
Drug 
Tolbutamide 
Chlorothiazide 
Demethylchlortetracycline 
Tetracycline base 
Furosemide 
Q4inidine 
Chlorpromazine 
Prochlorperazine 
Colchicine 
Chlordiazepoxide 
Dose 
injected 
(!'gm) 
500 
500 
0.2 
150 
200 
500 
250 
200 
200 
500 
250 
100 
250 
0.2 
100 
a Fraction of positive responders. 
UV-A 
(WG-345 
Filter) 
0!6" 
0/7 
0/ 7 
B/ 10 
7/16 
0/B 
7/ 9 
6/B 
5/6 
5/8 
Bill 
5/ 5 
6/7 
0/6 
0/7 
Solar 
simulating 
radiation (WG-
320 
Filter) 
BI B" 
Bi ll 
6/ 7 
0/ B 
0/ B 
0/ B 
10/15 
0/ 7 
0/7 
0/B 
0/7 
0/ B 
0!6 
0/6 
0/ B 
TABLE II. Influence of dose on the phototoxic responses to 
furosemide and quinidine 
Furosemide" Quinidine gluconate• 
Dose (!'gm) Number of Number of 
positive responders Dose (!'gm) positive responders 
1000 12/ 12 250 10/ 13 
250 7/ 12 62.5 4/ 13 
62.5 1/ 12 15.6 0/ 13 
a UV-A dose for furosemide was 15.0 Joules/ cm2• 
• UV -A dose for quinidine gluconate was B.O Joules/ cm2 . 
indicates phototoxic potentiality but allows no firm predictions 
regarding comparative phototoxic activity or frequency of clin-
ical reactions in conventional usage. Such data can only be 
procured by administering the test drug orally or parenterally. 
The solar simulator does not allow for a precise determination 
of action spectra. Nevertheless, by using various cut-off filters, 
we narrowed down the range of photoactivating wavelengths. 
Although most phototoxic agents, as expected, were activated 
by energy containing UV -A, there were important exceptions. 
Sulfonamides and vinblastin were activated by radiation con-
taining UV-B, while chlorothiazide photoxicity was elicited by 
UV-B as well as UV-A. 
There are conflicting reports concerning the action spectrum 
of sulfanilamide phototoxicity (Table Ill). Epstein [9] and Blum 
[10] years ago showed that the response is provoked by UV-B 
and can be abolished by window glass filtration. More recent 
reports incriminate wavelengths in the UV-A range [7,11]. 
The dogma that the action spectrum for photosensitizing 
drugs is in the UV -A region requires revision. For a few agents 
at least, such as sulfanilamide and vinblastin [12], the photoac-
tivating rays lie in the UV-B range. Evidence is accumulating 
that this may also be true of certain agents that cause contact 
photoallergy. It is standard teaching that the latter are acti-
vated by UV-A. Yet Jung found that the photoallergic reaction 
to the laxative triacetyldiphenolisatin was caused by UV-B and 
not by UV -A [13]. Emmett reported a case of diphenhydramine 
photoallergy that was provoked by UV-B [14]. 
Our negative findings with tolbutamide and chlordiazepoxide 
are also at variance with those of certain other investigators 
(see Table III) . It is possible that larger test concentrations of 
these drugs are required for eliciting phototoxic reactions. 
Nonetheless, it is our belief that these agents do not provoke 
phototoxicity. The photosensitivity eruptions imputed to tol-
butamide may be photoallergic in nature. 
An;mal studies are useful for preliminary screening. As yet 
no model has been described for which proof of high sensitivity 
has been provided. A screening technique should enable iden-
tification of substances which have been indisputably proved 
to cause photo toxicity in humans. Significant species differences 
have been reported with regard to phototoxicity [16]. Ramsey 
and Obreshkova failed to obtain responses with intradermal 
injections of nalidixic acid in mice [17]. Blum was unable to 
demonstrate sulfanilamide phototoxicity in rodents, even after 
repeated challenge [10]. This is also congruent with our own 
experience. Responses are difficult to evaluate in animals, even 
with the use of "bluing" agents that help to visualize edema. 
Furthermore, drugs may be metabolized differently in animals. 
In contrast to Kligman and Breit's observations [7], photo-
toxic reactions to sulfanilamide, tetracycline and chlorothiazide 
could not be regularly secured by topical application (unpub-
lished observations). We have, therefore, abandoned topical 
phototesting as a screening technique for agents intended for 
systemic use. 
Our current operating procedure is as follows: 0.1 ml of the 
test material is intradermally injected at a nonirritating concen-
tration in physiologic saline. An appropriate concentration can 
be selected after injecting a range of concentrations into the 
skin of rabbits or guinea pigs. Ultrasonification is an excellent 
way to prepare fine, uniform suspensions of insoluble drugs. 
Irradiation is given 10 min after injection. Exposure to UV-A 
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TABLE III. Results of phototoxicity testing for certain drugs (as reported by various authors) 
Drug, author(s) & 
reference number 
Route of 
administration UV sou
rce Phototoxicity Action spectrum 
Sulfanilamide 
Epstein (9] ID" (humans) Mercury Arc, (hot 
quartz) 
Yes 
Blum [10] ID (humans) 
ID (humans) 
Mercury Arc Yes 
Yes 
UV-B 
UV-A Kligman & Breit [7) 
Stratigos & Magnus [11] ID (hairless mice) 
Xenon Arc, (solar 
simulator) 
Monochromator Yes 375-400 nm 
Present study ID (humans) Xenon Arc Yes 
280-300 nm (questionably) 
UV-B 
Tolbutamide 
Ison & Blank [1] IP< (hairless mice) F -40 BL lamps No 
No (300-400 nm) Sun-
light 
Kligman & Breit [7] 
Present study 
ID (humans) 
ID (humans) 
Xenon Arc Yes 
No 
UV-A 
Xenon Arc 
Chlordiazepoxide 
Ison & Davis [15] IP (albino mice) F-40 BL lamps Yes UV-A 
Present study ID (humans) 
(300-400 nm) 
Xenon Arc No 
• ID = intradermal 
b NI = not investigated 
c IP = intraperitoneal 
and solar simulated UV should be carried out separately. Ex-
posures to UV-A should begin with about 30 Joules/cm2, in-
creasing up to 40 Joules/cm2, if necessary. For solar simulating 
radiation suberythemal doses are given initially (3/4 MED), 
increasing to 1'.5 MED's. Larger doses would result in excessive 
erythema which may obscure a phototoxic reaction. Grading 
should be done 24 hr after irradiation. 
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